A phase I/II trial of a tetravalent live attenuated dengue vaccine in flavivirus antibody naive children
Phase of Trial: Phase I/II
Latest Information Update: 30 Mar 2010
At a glance
- Drugs TDENV LAV (Primary)
- Indications Dengue
- Focus Adverse reactions; Pharmacodynamics
- 30 Mar 2010 Additional lead trial centre identified as United States Medical Materiel Development Activity as reported by ClinicalTrials.gov.
- 14 Feb 2008 The expected completion date for this trial is now 1 May 2004.
- 04 Nov 2006 New trial record.